Correspondence 0001493152-25-002402 from Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc.
Date: Jan. 15, 2025 · CIK: 0001583771 · Accession: 0001493152-25-002402
AI Filing Summary & Sentiment
File numbers found in text: 333-284052
Letter
Hepion Pharmaceuticals, Inc.
c/o Clementi Associates
919 Conestoga Road
Building 3, Suite 115
Rosemont, PA 19010
January 15, 2025
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jason Drory
Re:
Hepion Pharmaceuticals, Inc.
Form S-1 Registration Statement, as amended
Filed December 26, 2024
File No. 333-284052
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on January 14, 2025, in which we requested acceleration of the effective date of the above-referenced Registration Statement to January 15, 2025, at 5:00 p.m., Eastern Standard Time. We hereby formally withdraw our previous request for acceleration.
HEPION PHARMACEUTICALS, INC.
By: /s/ John Brancaccio
Name: John Brancaccio
Title: Interim Chief Executive Officer
-1-
Show Raw Text
CORRESP
1
filename1.htm
Hepion Pharmaceuticals, Inc.
c/o Clementi Associates
919 Conestoga Road
Building 3, Suite 115
Rosemont, PA 19010
January 15, 2025
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jason Drory
Re:
Hepion Pharmaceuticals, Inc.
Form S-1 Registration Statement, as amended
Filed December 26, 2024
File No. 333-284052
Ladies and Gentlemen:
Reference is made to our
letter, filed as correspondence via EDGAR on January 14, 2025, in which we requested acceleration of the effective date of the above-referenced
Registration Statement to January 15, 2025, at 5:00 p.m., Eastern Standard Time. We hereby formally withdraw our previous request for
acceleration.
HEPION PHARMACEUTICALS, INC.
By:
/s/ John Brancaccio
Name:
John Brancaccio
Title:
Interim Chief Executive Officer
-1-